Currently Viewing:
Newsroom
Currently Reading
FDA Approves Gene Therapy With $2.1M Price Tag for Spinal Muscular Atrophy in Pediatric Patients
May 24, 2019 – Jaime Rosenberg
Evobrutinib Reduced Signs of Active Inflammation in Patients with Multiple Sclerosis
May 24, 2019 – Wallace Stephens
AJMC® in the Press, May 24, 2019
May 24, 2019 – AJMC Staff
5 Key Policy Issues for Employers and Mental Health
May 24, 2019 – Mary Caffrey
What We're Reading: Bipartisan Healthcare Package; Colorado Caps Insulin Prices; FDA Authorizes Zika Diagnostic Test
May 24, 2019 – AJMC Staff
This Week in Managed Care: May 24, 2019
May 24, 2019
Suspension of a Rural Syringe Service Program Increased Risks of HIV and HCV Acquisition
May 23, 2019 – Wallace Stephens
How Cells Slow Cancer That Has Reached Bone
May 23, 2019 – Laura Joszt
LifeScan Finds Partner to Move Into CGM Market
May 23, 2019 – Mary Caffrey

BrainChild-01 Will Evaluate CAR T Cells in Pediatric CNS Tumors

Surabhi Dangi-Garimella, PhD
The trial is designed to test chimeric antigen receptor (CAR) T-cell therapy in children and young adults with relapsed/refractory brain and central nervous system (CNS) tumors, wherein the modified CAR T cells will be directly injected at the site of tumor resection or into the ventricular system of the CNS.
Researchers at the Seattle Children’s Hospital have initiated enrollment in the BrainChild-01 trial, which is designed to test chimeric antigen receptor (CAR) T-cell therapy in children and young adults with relapsed/refractory brain and central nervous system (CNS) tumors. Intriguingly, the modified CAR T cells will not be infused intravenously—rather, the cells will be injected either directly at the site of tumor resection or into the ventricular system of the CNS.  

According to the National Brain Tumor Society, about 28,000 US children are living with a brain tumor and about 4610 new cases of childhood and adolescent primary malignant and nonmalignant brain and CNS tumors are expected to be diagnosed in 2018. Brain tumors surpass leukemia as the leading cause of cancer-related deaths among children and adolescents.

Direct infusion of CAR T cells into the resected tumor cavity in the brain is also being evaluated in adult patients. Speaking at the recent annual meeting of the American Society of Clinical Oncology, Amy B. Heimberger, MD, professor, Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, told the audience that the process helps overcome the lack of T-cell infiltration in the tumor. Multiple intracranial infusions of IL13Rα2 CAR T cells in the resected tumor cavity of a patient with recurrent multifocal glioblastoma, as well as in the ventricular system, resulted in a regression of intracranial and spinal tumors in that patient. The response was sustained for 7.5 months.

The phase 1 BrainChild-01 study expects to recruit 26 patients with recurrent or refractory HER2-positive CNS tumors who will be treated with autologous CD4 and CD8 T cells transduced to express a HER2-specific CAR and EGFRt. Children with HER2-positive tumors that have relapsed or are refractory to prior treatment, and who meet the trial’s inclusion criteria, will undergo apheresis. The collected T cells will then be genetically modified to target them to HER2-expression tumor cells, and the modified cells will be administered through an indwelling catheter in 2 phases:
  • A weekly dose for 3 weeks followed by a week off and an examination period
  • Weekly dose for 3 weeks
Following evaluation of treatment impact, including magnetic resonance imaging, patients can receive 6 more courses of infusion if there are T cells available and if patients have not had adverse effects.

Primary outcomes that the study plans to measure include safety and feasibility of administering the CAR T-cell infusion directly into the tumor cavity.

Secondary study objectives include examining the distribution of CAR T cells in the cerebrospinal fluid, their diffusion into the blood stream, and, if possible, monitoring HER2 expression in the tumors at diagnosis versus at recurrence.

BrainChild-01, as the trial is named, will initially leave out patients diagnosed with diffuse intrinsic pontine gliomas, or DIPG tumors, which are highly aggressive tumors found at the base of the brain. However, Seattle Children’s Hospital plans to include children needing treatment for DIPG tumors in future BrainChild trials.

Related Articles

Northwestern Study Discovers Treatment For Pediatric Gliomas
Real-World and Phase 1 Safety Studies of Immuno-Oncology Agents in NSCLC and Glioblastoma
CAR T-Cells of Defined Composition Effective in Ibrutinib-Refractory CLL
Precision Genomic Panels a Vital Clinical Support Tool in Pediatric Brain Tumors
Researchers Categorize Incurable Childhood Brain Tumors as Separate Cancer Types
 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up